The move would create two independent, publicly traded companies — one of which offers branded specialty products, the other offering niche specialty generics and active pharmaceutical ingredient manufacturing.
Lupin has introduced generic nystatin and triamcinolone acetonide cream, which had a market value of $54.3 million, according to IQVIA data for the 12 months ended September 2018.